Chargement en cours...
Development of a palivizumab specialty pharmacy management program
Background: Palivizumab is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in high risk pediatric patients. Due to the high cost, handling requirements, administration route, and importance of adherence, palivizumab is best managed...
Enregistré dans:
| Publié dans: | J Drug Assess |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Taylor & Francis
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6764365/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21556660.2019.1658299 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|